1. Home
  2. PD vs XERS Comparison

PD vs XERS Comparison

Compare PD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

N/A

Current Price

$7.58

Market Cap

987.5M

Sector

Technology

ML Signal

N/A

XERS

Xeris Biopharma Holdings Inc.

N/A

Current Price

$5.77

Market Cap

965.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PD
XERS
Founded
2009
2005
Country
United States
United States
Employees
N/A
435
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
987.5M
965.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
PD
XERS
Price
$7.58
$5.77
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
$17.00
$10.43
AVG Volume (30 Days)
3.5M
2.0M
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
33.71
100.00
EPS
1.73
N/A
Revenue
$467,499,000.00
$49,590,000.00
Revenue This Year
$8.16
$28.65
Revenue Next Year
$3.75
$18.33
P/E Ratio
$4.60
N/A
Revenue Growth
8.54
142.67
52 Week Low
$6.18
$3.81
52 Week High
$19.70
$10.08

Technical Indicators

Market Signals
Indicator
PD
XERS
Relative Strength Index (RSI) 42.83 30.81
Support Level $6.18 $4.30
Resistance Level $16.48 $7.21
Average True Range (ATR) 0.37 0.38
MACD 0.29 -0.07
Stochastic Oscillator 74.40 15.56

Price Performance

Historical Comparison
PD
XERS

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: